Fenwick Represents BioPharmX in $10 Million Initial Public Offering

Fenwick & West represented BioPharmX (NYSE: BPMX), which is developing therapies for fibrocystic breasts and acne, in its initial public offering. The company offered 3,636,364 shares of its common stock to the public at a price of $2.75 per share. In addition, the company granted the underwriters a 30-day option to purchase up to an additional 545,454 shares of common stock.

CRT Capital acted as lead book-running manager for the offering. Feltl and Company and Newbridge Securities Corporation acted as co-managers.

The Fenwick transaction team included corporate attorneys Robert Freedman, Niki Fang, Philip Henry and Alyssa Martin; executive compensation and employee benefits attorney Grace Chen; and patent attorney Michael Shuster.